Business Wire

Westinghouse-styrt konsortium redo att leverera bränsle till VVER-440-reaktorer i Europa

Share

Westinghouse Electric Company och dess åtta europeiska partner i konsortiet tillkännagav idag att de framgångsrikt har slutfört ett EU-finansierat projekt som syftar till att diversifiera kärnbränsleförsörjningen till reaktorer av typen VVER-440 i Europa.

Konsortiet har framtagit ett koncept för bränslekonstruktion och fastställt hur tillverkningen och leveranskedjan för att bygga och transportera bränsleknippen tillhörande VVER-440 kan återupprättas, i likhet med vad Westinghouse och ENUSA genomförde för Lovisa kärnkraftverk i Finland 2001–2007. Utöver bränslekonstruktionen har konsortiet infört och verifierat de därtill hörande metoder som ska tillämpas med avseende på licensiering och användning av en ny bränslekonstruktion.

”Genom det här projektet är vi mycket väl förberedda för att tillverka och leverera VVER-440-bränsle till europeiska anläggningar. Därmed har vi skapat ett gångbart alternativ för dagens bränsleförsörjning som kommer från en enda källa”, säger Aziz Dag, Vice President och Managing Director för norra Europaregionen. ”Många länder i Östeuropa är starkt beroende av kärnenergi, vilket strategiskt sett gör det mycket viktigt att trygga deras energiförsörjning.”

Westinghouse har ansvarat för projektet, som går under namnet European Supply of Safe Nuclear Fuel (ESSANUF), sedan september 2015. I projektet deltar VUJE, ÚJV Řež, Villmanstrands tekniska universitet, National Nuclear Laboratory (NNL), NucleoCon, National Science Center Kharkov Institute of Physics and Technology (NSC KIPT), Europeiska kommissionens gemensamma forskningscentrum i Karlsruhe (JRC-Karlsruhe) samt ENUSA Industrias Avanzadas (ENUSA). Programmet finansieras av Euratoms forsknings- och utbildningsprogram (EU) (2014–2018), som är en del av Horizon 2020 (H2020), Europeiska unionens program för forskning och innovation (bidragsöverenskommelse 671546).

Detta meddelandes ursprungliga källspråkstext är den officiella versionen. Översättningar tillhandahålls endast som ett stöd och skall jämföras med källspråkstexten, vilken är den enda versionen av texten som har rättslig verkan.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Westinghouse Electric Company
Sarah Cassella, 412-374-4744
Chef för extern kommunikation
cassels@westinghouse.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye